65,437 trials
Diabetes · Diabetes Mellitus, Type 2
Primary: Change in Glycosylated Haemoglobin A1c (HbA1c) at Week 20 — 9.3; 8.2; -1.2 percentage change in HbA1c — p=<.0001
HIV Infection
Primary: Number of Participants Who Discontinued Treatment Due to Adverse Events — 12; 3; 3; 1 Participants
HIV Infections
Primary: Number of Patients With a Viral Load< 50 Copies/mL and a Gain in CD4 Higher Than 100 Cells/mm3 — 8 participants
Influenza
Primary: Number of Participants With at Least 1 Solicited Injection Site Solicited Systemic Reactions Post-vaccination With Fluzone® Vaccine. — 35; 18; 34; 16 Participants
Lupus Nephritis
Primary: Percentage of Participants Who Achieved a Complete Renal Response (CRR), a Partial Renal Response (PRR), or no Renal Response (NRR) at Week 52 — 26.4; 30.6; 30.6; 15.3…
Oral Epithelial Dysplasia, Mild or Moderate Grade
Primary: The Number of Participants With Both Clinical and Histological Evidence of Malignant Transformation of Oral Epithelial Dysplasia — 32; 46 participants
Bipolar Disorder · Depression, Bipolar
Primary: Change From Baseline to Week 6 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score — -14.7; -13.2 scores on scale — p=0.7921
Type 2 Diabetes Mellitus
Primary: Analysis of Test for Positive Efficacy Trend in Change From Baseline in Hemoglobin A1c (A1C) at Week 12 in the 0-40 mg Cohort — -0.67; -0.95; -0.81; -0.74 percentage of…
Purpura, Thrombocytopaenic, Idiopathic
Primary: Percentage of Responders — 2; 1; 7; 37 Percentage of participants — p=<0.001
Alzheimer's Disease · Dementia
Primary: Multidimensional Observation Scale for Elderly Subject — 69.75; 77.99 Units on a scale
Schizophrenia
Primary: Long-term Change in Negative Symptoms of Schizophrenia Measured by the Negative Symptom Assessment (NSA) Scale — -16.9; -15.4 Units on a Scale
Attention Deficit Hyperactivity Disorder (ADHD)
Primary: Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale-fourth Edition (ADHD-RS-IV) Total Score at up to 4 Weeks — -18.3; -21.1; -20.7; -12.8 Units…
Hepatitis C
Primary: Number of HCV LVL G1 Participants Who Relapsed — 16 Participants
Narcolepsy · Sleep Apnea, Obstructive · Sleep Apnea Syndromes
Primary: Safety and Tolerability as Measured by Number of Participants With Adverse Events — 323 Participants
Menorrhagia · Heavy Menstrual Bleeding
Primary: Mean Reduction From Baseline in Menstrual Blood Loss (MBL) — 66; 18 mL